Flüssigkeitsgabe bei Ketoazidose (DRINK) (DRINK)
Vergleich von Kochsalzlösung und Ringer-Laktat bei Patienten mit schwerer diabetischer Ketoazidose (DRINK): eine doppelblinde, randomisierte, kontrollierte Studie
Management of severe diabetic ketoacidosis is based on insulin therapy, correction of metabolic disorders and fluid resuscitation. Current recommendations recommend the first-line use of isotonic saline, whose composition is unbalanced, rich in chloride and sodium compared with plasma. Administration of large volumes of isotonic saline is associated with a risk of hyperchloremic metabolic acidosis and acute renal failure. Balanced solutions (e.g. Ringer Lactate) are solutions with a more balanced electrolyte composition close to that of plasma. They could therefore enable diabetic ketoacidosis to be resolved more quickly than isotonic saline, due to a lower risk of hyperchloremic acidosis. Preliminary data suggest a potential benefit of balanced solutions for fluid resuscitation of patients with severe diabetic ketoacidosis in terms of resolution of diabetic ketoacidosis, but no randomized controlled double-blind study to date has compared balanced solution vs. isotonic saline in this context.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 4
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Mathieu JOZWIAK, MD PhD
- Telefonnummer: +33492035510
- E-Mail: jozwiak.m@chu-nice.fr
Studienorte
-
-
-
Nice, Frankreich
- Rekrutierung
- CHU NICE
-
Kontakt:
- MATHIEU JOZWIAK, MD PhD
- Telefonnummer: +33492035510
- E-Mail: jozwiak.m@chu-nice.fr
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Admission to emergency department or direct admission to ICU
- Diagnosis of severe diabetic ketoacidosis requiring all the following criteria:
- Blood or capillary glucose > 11 mmol/L
- Ketonemia or ketonuria > 0
- Venous or arterial pH < 7.30 or venous or arterial bicarbonate < 15 mmol/L
- Volume of fluid administered before inclusion <1L
Exclusion Criteria:
- Patients <18 years
- Pregnant women
- Patients under protection
- Patients with a decision to withdraw life-sustaining therapy
- Contraindication to isotonic saline or Ringer Lactate
- Non-affiliation to social security
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Isotonische Kochsalzlösung
|
Isotonic saline only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:
|
|
Experimental: Ringer-Laktat
|
Ringer Lactate only will be used for fluid resuscitation in the first 48 hours of treatment, according to the protocol of English guidelines:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Resolution of diabetic ketoacidosis
Zeitfenster: at 24 hours
|
Compare fluid resuscitaiton with Ringer Lactate to isotonic saline on the resolution of diabetic ketoacidosis at 24 hours from admission to Intensive Care Unit (ICU) in patients with severe diabetic ketoacidosis. Resolution of ketoacidosis allowing discharge from ICU, defined as the proportion of patients with the following three criteria at 24 hours from ICU admission :
|
at 24 hours
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Speed of resolution of metabolic disorders
Zeitfenster: at 48 hours
|
Compare fluid resuscitation with Ringer Lactate and isotonic saline solution on the speed of resolution of metabolic disorders in patients admitted to ICU for severe diabetic ketoacidosis. Proportion of patients and number of hours ("Resolution free hours") within 48 hours of ICU admission with the following three criteria:
|
at 48 hours
|
|
Time of resolution of metabolic disorders
Zeitfenster: at 48 hours
|
Compare fluid resuscitation with Ringer Lactate and isotonic saline solution on the speed of resolution of metabolic disorders in patients admitted to ICU for severe diabetic ketoacidosis. Time (in hours) from ICU admission to obtain one of the following three criteria:
|
at 48 hours
|
|
Assess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution
Zeitfenster: through the end of study average 24 months
|
Assess the metabolic tolerance of Ringer Lactate compared to isotonic saline solution in patients admitted to ICU for severe diabetic ketoacidosis. Occurrence of serious metabolic disorders during ICU stay, defined as :
|
through the end of study average 24 months
|
|
Assess the impact of Ringer lactate compared with isotonic saline on renal, neurological and cardiac complications
Zeitfenster: at 28 days
|
To assess the impact of Ringer lactate compared with isotonic saline on renal, neurological and cardiac complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis. Occurrence of adverse events during ICU stay, defined as :
|
at 28 days
|
|
Assess the impact of Ringer lactate compared with isotonic saline on cardiac complications
Zeitfenster: at 28 days
|
To assess the impact of Ringer lactate compared with isotonic saline on cardiac complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis. Occurrence of adverse events during ICU stay, defined as :
|
at 28 days
|
|
Assess the impact of Ringer lactate compared with isotonic saline on renal complications
Zeitfenster: at 28 days
|
To assess the impact of Ringer lactate compared with isotonic saline on renal, complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis. Measure acute renal failure with KDIGO classification. The Kidney Disease: Improving Global Outcomes (KDIGO) classification system stratifies acute kidney injury (AKI) into levels of severity, determined by changes in serum creatinine (SCr) / estimated creatinine clearance (eCCl), as well as changes in urine output. The strata of severity of AKI can be reached by meeting the criteria for changes in SCr / eCCl or changes in urine output. There are three levels of severity, with level 1 being the least severe and level 3 the most severe. No cut-off for the study |
at 28 days
|
|
Assess the impact of Ringer lactate compared with isotonic saline on neurological complications
Zeitfenster: at 28 days
|
To assess the impact of Ringer lactate compared with isotonic saline on neurological complications during ICU stay and outcomes of patients admitted to ICU for severe diabetic ketoacidosis. Measure Neurological disorders with Glasgow score. The Glasgow Coma Scale (GCS) is used to objectively describe the extent of impaired consciousness in all types of patients. The scale rates patients on three aspects of reactivity: eye opening, motor responses and verbal responses. It ranges from 3 (coma) to 15 (no disturbance of consciousness). No cut-off for the study. |
at 28 days
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 22-API-03
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .